Myclausen (Mycophenolate Mofetil)

Myclausen is an antimetabolite immunosuppressant that acts on the immune system to reduce lymphocyte proliferation.

• Organ transplant rejection: helps prevent graft rejection after kidney, heart or liver transplantation.
• Lupus nephritis: reduces kidney inflammation in patients with systemic lupus erythematosus.
• Autoimmune vasculitis: used as part of therapy for certain systemic vasculitic disorders.

• Mycophenolate Mofetil selectively inhibits inosine monophosphate dehydrogenase (IMPDH), the key enzyme for de novo guanosine nucleotide synthesis. This limits guanosine pools, suppressing proliferation of T‑ and B‑lymphocytes that rely on this pathway, thereby reducing immune activation and graft rejection.

Myclausen may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: frequent loose stools.
• Headache: intermittent pain.
• Hypertension: elevated blood pressure.
• Infections: increased susceptibility to bacterial or viral infections.
• Anemia: reduced red blood cell count.

Serious or Rare Side Effects

• Opportunistic infections: such as Pneumocystis jirovecii pneumonia.
• Severe neutropenia: markedly low white blood cells.
• Hepatotoxicity: liver enzyme elevations or injury.
• Malignancy: increased risk of certain cancers with long‑term use.
• Gastrointestinal perforation: rare but serious bowel injury.

Before prescribing Myclausen, clinicians should consider several safety measures.

• Monitor blood counts: regular CBC to detect leukopenia or anemia.
• Assess renal function: adjust dose in patients with impaired kidney function.
• Contraindicated in pregnancy: drug is classified as Category X and must be avoided.
• Avoid live vaccines: immunosuppression can reduce vaccine efficacy and increase risk.
• Review concomitant nephrotoxic agents: limit use with drugs that may further harm kidneys.
• Store below 25°C: keep in the original pack, protect from moisture.

Myclausen can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• Azathioprine: additive bone‑marrow suppression.
• Cyclosporine or tacrolimus: increased mycophenolate exposure, risk of toxicity.
• Cholestyramine or colestipol: reduced absorption of mycophenolate.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may decrease drug bioavailability.
• Warfarin: potential alteration of anticoagulant effect.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.